PDUFA Fee Waiver comes Days before Planned Submission of New Drug ApplicationKANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

Cingulate developed CTx-1301 using its precision timed release (PTR) drug delivery platform. The drug contains dexmethylphenidate, an FDA-approved stimulant used to treat ADHD. Patients with ADHD ...

View Cingulate, Inc. CING stock quote prices, financial information, real-time forecasts, and company news from CNN.

Cingulate, Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform technology. The company, founded in 2013, aims ...

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301 ...

Cingulate By Grace Mayer – Staff Writer, Kansas City Business Journal Jan 29, 2024 Updated Jan 30, 2024 5:19pm CST Preview this article 1 min ...

Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical ...

Cingulate has applied the technology to two attention-deficit hyperactivity disorder candidates and the anxiety prospect but has seen investor interest dwindle over the past year, a period in ...